Results from the BEVA2007 trial, suggest that the metronomic chemotherapy regimen with dose-fractioned cisplatin and oral etoposide (mPE) +/− bevacizumab, a monoclonal antibody to the vascular endothelial growth factor (VEGF), shows anti-angiogenic and immunological effects and is a safe and active treatment for metastatic non-small cell lung cancer (mNSCLC) patients. We carried out a retrospective analysis aimed to evaluate the antitumor effects of this treatment in a subset of patients with squamous histology. Methods: Retrospective analysis was carried out in a subset of 31 patients with squamous histology enrolled in the study between September 2007 and September 2015. All of the patients received chemotherapy with cisplatin (30 mg/sqm, days 1-3q21) and oral etoposide (50 mg, days 1-15q21) (mPE) and 14 of them also received bevacizumab 5 mg/kg on the day 3q21 (mPEBev regimen). Results: This treatment showed a disease control rate of 71% with a mean progression free survival (PFS) and overall survival (OS) of 13.6 and 17 months respectively. After 4 treatment courses, 6 patients showing a remarkable tumor shrinkage, underwent to radical surgery, attaining a significant advantage in term of survival (P=0.048). Kaplan-Meier and log-rank test identified the longest survival in patients presenting low baseline levels in neutrophil-to-lymphocyte ratio (NLR) (P=0.05), interleukin (IL) 17A (P=0.036), regulatory-T-cells (T reg s) (P=0.020), and activated CD83+ dendritic cells (DCs) (P=0.03). Conclusions: These results suggest that the mPE +/− bevacizumab regimen is feasible and should be tested in comparative trials in advanced squamous-NSCLC (sqNSCLC). Moreover, its immune-biological effects strongly suggest the investigation in sequential combinations with immune check-point inhibitors.
Introduction
Non-small cell lung cancer (NSCLC) is the most common malignancy and the leading cause of cancer death representing about 17% of new cancer diagnoses worldwide (1, 2) . Squamous-NSCLC (sqNSCLC) (3) represents the second most common histology (30% of all cases), and for these patients the only chance of cure is represented by radical surgery that is possible only in case of loco-regional disease (stage I-IIIA) and good performance status. The standard treatment for advanced sqNSCLC patients (stage IIIB-IV) with a good performance status is represented by chemotherapy with platinum derivatives cisplatin or carboplatin in combination with gemcitabine, paclitaxel or nab-paclitaxel and, eventually, radiotherapy for palliation (4) (5) (6) . In this light, patients with advanced sqNSCLC have a poor prognosis with a survival that usually does not exceed 9-10 months and with no real improvement attained with systemic treatments in the last three decades (4) . The longlasting therapeutic failure for advanced sqNSCLC patients has been recently interrupted by the positive results of clinical trials testing programmed-cell-death-receptor-1 (PD-1)/programmed-cell-death-receptor ligand-1 (PDL-1) immune-checkpoint blockade with monoclonal antibodies (mAbs) such as Nivolumab, Pembrolizumab or Atezolizumab. These results lead the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) to approve some of these agents for the second line treatment of advanced sqNSCLC patients (7) (8) (9) (10) . We have previously designed a multistep phase I/II clinical trial (Beva 2007 study) aimed to investigate the toxicity, the biological and anti-tumor activity of a novel metronomic chemotherapy regimen with dose-fractioned cisplatin and oral etoposide (mPE) +/− bevacizumab (mPEBev) in NSCLC patients, including the squamous cell histology. Metronomic chemotherapy is an emerging treatment modality for cancer patients based on the use of cytotoxic drugs administered at lower dosage for a prolonged period of time (11) . This modality allows to achieve a higher dose intensity of cytotoxic drugs compared to traditional modality avoiding dangerous spikes in blood concentration (12, 13) . Some of these properties may be enforced by a rationale combination with bevacizumab, a humanized IgG1 to the vascular endothelial growth factor (VEGF), able to increase the efficacy of standard poly-chemotherapy in NSCLC patients (14, 15) . Metronomic chemotherapy and VEGF deprivation by bevacizumab synergize as both anti-angiogenic and immune-modulating activity, resulting in a significant antitumor activity. Even though considered a very active drug for NSCLC patients, bevacizumab was not approved for the treatment of sqNSCLC due to the high risk of bleeding reported in the early trials. This risk was correlated to the central localization of the disease that often infiltrates the large mediastinum vessels. Considering the lowest dosage and chronic administration of the treatment, our trial also included NSCLC patients with squamous histology with low risk of bleeding. The mPEBev regimen resulted safe and very active with a partial response and disease stabilization rate of 68.8% and 17.8%, respectively, and a progression free survival (PFS) of 9.5 months (16, 17) . The treatment was associated to a fast and progressive decline in the tumor blood flux (perfusional CT scan) paralleled by a progressive decline in the serum levels of pro-angiogenic and immune-modulating cytokines (VEGF, angiopoietin-1, thrombospondin-1, follistatin, IFNɣ, IL-4 and IL-17A), and inflammatory markers [neutrophil-lymphocyte ratio (NLR), C reactive protein (CRP), lactate dehydrogenase (LDH), myeloperoxidase] (17, 18) . Additional in vivo and ex vivo immunological studies also revealed a treatment-related improvement in both tumor antigen processing and presentation ability by active peripheral dendritic cells (DCs) and a more efficient tumorspecific cytotoxic T cell (CTL) response (18) suggesting that either mPE or mPEBev regimens may improve the micro-environmental conditions necessary for an efficient anti-tumor activity by antigen specific T cell effectors. At this purpose, we performed a retrospective analysis aimed to evaluate the antitumor activity of the mPE regimen +/− bevacizumab, in the subset of patients with sqNSCLC histology enrolled in the second step of the BEVA2007 trial and, also, carried out a statistical analysis aimed to identify possible immunobiological markers predictive of positive outcome in these patients.
Methods

Study design
The study protocol code #BEVA2007 (2008-006051-40) was a two-step phase I/II clinical trial, performed in accordance to the good clinical practice guidelines and was approved by the Bioethics Committee of the University of Siena as described in previous reports (16) (17) (18) . The first step of the study included 25 patients, who were sub-divided in five cohorts receiving escalating dosage of bevacizumab. Cohort 1 received mPE chemotherapy alone, while cohort 2, 3, 4 and 5 received bevacizumab every three weeks, at the dosage of 2.5, 5, 7.5 and 10 mg/kg every three weeks. This first step revealed coincidence of bevacizumab maximal tolerated dose (MTD) and most effective biological dose (MEBD) at 5 mg/kg (16) , which was chosen as standard dosage for the second step of the study. The inclusion criteria were: histological diagnosis of mNSCLC, performance status (ECOG) from 0 to 2, normal renal and hepatic function, WBC count more than 2,500/mm 3 , hemoglobin more than 9 g/dL, platelet cell count more than 90,000/mm 3 , normal cardiac function.
The exclusion criteria were: Central tumors with high risk of bleeding (excavated with large necrosis and infiltration of large arterial and venous structures) for bevacizumab use, a history of other severe cardiovascular disease, arrhythmia, second malignant tumors, signs of active infections. The trial included a calibration group of thirty patients who were aimed to receive the same metronomic chemotherapy and no bevacizumab. Four patients in the mPEBev group and two patients in the calibration group retired the consent and did not receive the treatment.
Treatment schedule
Eighty six patients received, every three weeks, iv. cisplatin (30 mg/sqm) on days 1-3 and daily oral etoposide (50 mg) on days 1-15 and bevacizumab, 5 mg/kg, on the day 3 for a maximum of four consecutive courses (16) (17) (18) . In the calibration group, twenty eight patients received the same metronomic chemotherapy with no bevacizumab administration. The response was assessed according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
Biological analysis and blood sampling
Peripheral blood samples (10 mL) were withdrawn at baseline and one hour before any treatment cycle for both serum and PBMC isolation. Serum derived from standard peripheral blood centrifugation and peripheral blood mononuclear cells (PBMCs), obtained by FicollHypaque (Celbio S.P.A., Italy) gradient separation medium from heparinized blood samples, were immediately frozen and stored as described in previous studies (16) (17) (18) . Lymphocytes, platelets, neutrophils and monocytes were evaluated by hemocytometric cell counts, while their feature was evaluated by microscope analysis. Flow cytometry was performed on patients' PBMCs by carrying out standard multicolor immuno-cytoflurimetric analysis with conjugated anti-CD3, CD4, CD8, CD27, CD62L, CD19, CD16, CD56, CD25, FoxP3, CCR7, CD45Ra, CD11b, CD11c, CD14, CD15, all purchased by Bioscience, USA.
BioPlex assay
Blood samples were collected from a peripheral vein at baseline and after 3 treatment courses and kept on ice. Serum was collected by centrifugation (3,000 rpm for 10 min at 4 ℃), aliquoted and stored at −80 ℃ until analyzed. A multiplex biometric ELISA-based immunoassay, containing dyed microspheres conjugated with a monoclonal antibody specific for a target protein was used according to the manufacturer's instructions (Bio-Plex, BioRad Lab., Inc., Hercules, CA, USA). Soluble molecules were measured using either commercially available kits or customized kits for the evaluation of the following cytokines: interleukin (IL)-4, IL-8, IL-10, IL-12, IL-17, interferon (IFN)ɣ, tumor necrosis factor (TNF)α, VEGF, Granulocyte-Colony Stimulating Factor (GCSF) and angiopoietin-2, as described in previous papers (16) . Serum levels of all proteins were determined using a Bio-Plex array reader (Luminex, Austin, TX, USA) that quantifies multiplex immunoassays in a 96-well plate with very small fluid volumes. The analyte concentration was calculated using a standard curve, with software provided by the manufacturer (Bio-Plex Manager Software).
Statistical analysis
The between-mean differences were statistically analyzed using Stat View statistical software (Abacus Concepts, Berkeley, CA, USA). The results were expressed as the mean +/− standard deviation (SD) of four determinations made in three different experiments, and the differences determined using the 2-tail Student's t-test for paired samples. In order to perform a survival analysis we divided the patients into two subgroups with low (L) and high (H) score, according to their respective median value of each specific marker or treatment related level change expressed as fold change to baseline value. Kaplan Meier's method and Log-Rank test were used to evaluate PFS and OS and correlate them with patients' associated variables. All analyses were performed by using SPSS statistical package, version 17.0. A P value of 0.05 or less was considered statistically significant.
Results
The BEVA2007 study was a multistep phase I-II trial aimed to investigate, in advanced NSCLC patients, the safety, immunobiological and antitumor activity of the mPE doublet +/− bevacizumab, an original metronomic chemo-biological regimen that showed significant antiangiogenic and immunological activity in previous studies (13, (16) (17) (18) 
Clinical results
The treatment was safe in patients with advanced sqNSCLC. They received a median number of four treatment courses with no significant toxicity or toxicity-related delay among the chemotherapy courses. No toxic death, bleeding episodes or severe infections were recorded; however, we recorded slight hematological toxicity mainly consisting in reversible grade 1-3 leukopenia (6 cases) rapidly recovered with the use of growth factors, grade 2 anaemia (6 cases), grade 1-2 gastroenteric toxicity (3 cases), grade 2-3 infections (3 cases) and alopecia (16 cases). Two patients required blood transfusions after three treatment courses and required a 25% cisplatin dose reduction. The latter two patients did not show any sign of bleeding and the anaemic state was consistent with a clinical picture of cisplatin related haematological toxicity which also involved blood cells and platelets. No case of treatment-related lethargic encephalitis or lung fibrosis was recorded in these patients; this was not surprising considering that bevacizumab was administered at the dosage of 5 mg/kg which is two/three times lower than that commonly used for the treatment of non-squamous NSCLC patients. The treatment showed a promising antitumor activity in these sqNSCLC patients; in fact, complete response (histologically confirmed) was obtained in 1, a partial response in 17 out of 31, a stable disease in 4 out of 31 and a progressive disease in the remaining 9 out of 31 patients, respectively. We also recorded a mean PFS and OS of 13.6±4. (Figure 2A,B,C) .
Biological correlations
The mPE chemotherapy regimen +/− bevacizumab Figure 4A,B) . These data support the hypothesis of a strong involvement of immune-system in the outcome of these patients. Patients who presented a treatmentrelated decrease in IL-17A levels showed a trend to a longer survival, which did not achieve statistical significance, probably due to the small statistical patient sample. No significant differences were, on the other hand, observed for other examined parameters.
Discussion
Our retrospective analysis, carried out on a subset of thirty-one advanced sqNSCLC patients enrolled in the second step of BEVA2007 trial, revealed a 71% disease control rate (complete response, partial response and stable disease) with a PFS and OS respectively of 13.6±4. bias does exist, due to both the small statistical sample of the patients and the retrospective nature of our analysis, these results appear promising considering that the most commonly used chemotherapy doublets induce in these patients a response rate of 25-40% and a median survival no longer than 9-10 months (4,6). In particular, we found that a systemic baseline inflammatory profile characterized by a low LNR, low levels of IL-17A and T reg s, and a high baseline expression of active DCs (CD83 + ), is predictive of longer survival (19) (20) (21) . It has been proposed that a chronic inflammation status supports tumor progression by increasing growth factors, chemokines and cytokines; they also promote inflammation-related neo-angiogenesis and both homing and differentiation of immunesuppressive cell lineages like myeloid derived suppressive cells (MDSCs) and T reg s (21-25). T reg s, whose activation is under control of CTLA-1 checkpoint, have the specific ability to attenuate the extent of cancer associate immuneresponse and represents a common mechanism of immuneescape for cancer cells (26) (27) (28) (29) . IL-17A is able to promote A B the switch of inactive T reg s in highly suppressive subsets that, in turn, can inhibit all the attempts of immune-system and tumor-specific CTLs to counteract tumor growth and development (29) (30) (31) (32) another very active CTL subset expressing the L selectin (CD62L), a trans-membrane protein which allows the binding to the specific receptor on tumor vessels and the consequent extravasation in the tumor sites (37) . In our patients, we also found a significant increase of peripheral DCs expressing CD83 and CD80, a very efficient antigen presenting cell linage able to uptake and process antigen released by tumor tissues exposed to the cytotoxic drugs (38) . Moreover, we recorded a longer survival in those patients who showed a higher treatment-related increase in activated DCs. These immunological effects, also described in previous studies (13, (16) (17) (18) , have been partially related to the metronomic modality of administration and can be also sustained by bevacizumab. The latter is known for its ability in inhibiting endothelial cell proliferation and neo-vessel formation and in inducing vessel normalization in cancer patients; however, it also promotes neutrophils', MSDCs', and T reg s' maturation and induces inhibitory effects on DC maturation and CTL precursors' activation (39) (40) (41) (42) . On this basis, it is not surprising that our metronomic chemotherapy +/− bevacizumab exerts immunological effects that may affect NSCLC patients' survival. These results may acquire additional interest for the recent development of immunotherapy based on PD-1/PDL1 immune-check point inhibitors in the treatment of mNSCLC, including squamous cell carcinoma (43) (44) (45) (46) (47) (48) . In this view, the presence of PD1 + T cells in tumor tissue is a consequence of pre-existing tumor specific immune-response that can be restored by anti-PD-1/PDL-1 mAbs such as nivolumab, pembrolizumab, and atezolizumab. These agents have shown promising antitumor activity in different neoplasms including melanoma, NSCLC, kidney and colon cancer and it is clear that their efficacy is strictly related to a pre-existing antitumor immune-response, which has been at least partially attenuated by PD-1/PDL-1 checkpoint and that is the ultimate weaponry able to kill tumor cells.
Conclusions
Based on our results, we believe that a possible way for improving the efficacy of mAbs in sqNSCLC patients could consist in testing a frontline treatment like mPEBev that mobilizes a large number of immune cells inducing an antitumor immunization followed by PD-1/PDL-1 checkpoint inhibitors. In conclusion, the mPE +/− bevacizumab regimen is an active treatment for advanced sqNSCLC patients and deserves additional evaluation in larger studies. Moreover, the immunological effects recorded in this trial can represent a solid basis to propose the mPE +/− bevacizumab regimen in a sequential combination with PD-1/PDL-1 immune-checkpoint inhibitors.
